Figure 20 is titled “Change in CAPS for atypical antipsychotics compared with placebo.” The figure displays a forest plot reporting the standardized mean difference in CAPS stratified by risperidone compared with placebo and olanzapine compared with placebo. This figure is described further in the “PTSD symptoms” section as follows: “For risperidone, four trials compared CAPS-assessed PTSD symptoms between treatment and placebo subjects and found some evidence of efficacy (SMD, −0.26, 95% CI, −0.52 to −0.01; I2=21.1%; 4 trials; N=422; Figure 20; low SOE). One trial found no real differences between groups; two suggested benefit but found no significant differences in PTSD symptoms between risperidone and placebo; and one trial found modest but very imprecise evidence of risperidone benefit.” The pooled meta analytic evidence from risperidone and olanzapine trials demonstrated efficacy of the class of atypical antipsychotics on CAPS-assessed PTSD symptoms (SMD, −0.37; 95% CI −0.74 to 0.00).

Figure 20Change in CAPS for atypical antipsychotics compared with placebo

CAPS = Clinician-Administered PTSD Scale; CI = confidence interval; PTSD = posttraumatic stress disorder; SIPS = Single Item PTSD Screener; SMD = standardized mean difference.

From: Results

Cover of Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update
Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update [Internet].
Comparative Effectiveness Review, No. 207.
Forman-Hoffman V, Middleton JC, Feltner C, et al.
Copyright Notice

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.